RPRX Royalty Pharma plc
Debt Financing ·
Royalty Pharma signed a $1.8 billion unsecured revolving credit facility maturing May 22, 2031, and repaid its 2021 facility in full. The covenants cap funded debt at 4.00 times Adjusted EBITDA, and the exhibit names a different borrower from the 8-K.
Zenas BioPharma sold Royalty Pharma a share of future obexelimab revenue for up to $300 million. It received $75 million at closing, and the other three $75 million payments depend on a Phase 3 milestone and two FDA approvals. The company says the cash lasts into the first quarter of 2027.
Royalty Pharma will pay $75 million upfront for a 5.5% royalty on worldwide net sales of obexelimab, with three more $75 million payments tied to milestones.
Royalty Pharma Holdings Ltd also assumed a $380 million term loan facility. The 8-K reports a loan amendment with Bank of America, N.A., an exchange agreement and amended articles of association.
Royalty Pharma says it is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the industry. It holds royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Johnson & Johnson's Tremfya, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, and royalties on 20 development-stage product candidates. In 2025 it generated $3.3 billion of Portfolio Receipts, which it defines as royalty receipts plus milestones and other contractual receipts. It announced transactions with a total potential value of $4.7 billion and deployed $2.6 billion of cash in 2025. The company estimates the biopharmaceutical royalty market reached $10.0 billion in transaction value in 2025, and it says it holds approximately 48% of royalty transactions from 2020 through 2025. Royalty Pharma describes royalties as non-dilutive capital that lets biotechnology companies keep operational control of their programs. The company was founded in 1996.
| Product or program | What it is | Stage |
|---|---|---|
| Trikafta | Vertex cystic fibrosis medicine on which Royalty Pharma holds a royalty | commercial |
| Trelegy | GSK product on which Royalty Pharma holds a royalty | commercial |
| Tysabri | Biogen product on which Royalty Pharma holds a royalty | commercial |
| Amvuttra | Alnylam product on which Royalty Pharma holds a royalty | commercial |
| Trodelvy | Gilead product on which Royalty Pharma holds a royalty | commercial |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.38 billion | $2.26 billion |
| Research and development | $452.0 million | $2.0 million |
| Net income (loss) | $770.9 million | $859.0 million |
| Cash from operations | $2.49 billion | $2.77 billion |
| Cash and equivalents | $618.7 million | $929.0 million |
| Short-term investments | $18.8 million | $58.2 million |
Royalty Pharma plc trades under the ticker RPRX on NASDAQ.
Royalty Pharma plc is listed on NASDAQ. Our directory also records these other listings: BMV:RPRX/N; DUS:RPD; FWB:RPD; GETTEX:RPD; HAM:RPD; HAN:RPD; LS:A2P62D; LSX:A2P62D; MUN:RPD; SWB:RPD; TRADEGATE:RPD; XETR:RPD.
The SEC Central Index Key (CIK) for Royalty Pharma plc is 1802768. Its filings are on SEC EDGAR.
388,132,400 shares as of 2020-11-10, per the cover page of its 10-Q filed 2020-11-12.
Our directory records Royalty Pharma plc under United States.
Our directory classifies Royalty Pharma plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Royalty Pharma plc is GB00BMVP7Y09.
aibio.space lists Royalty Pharma plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as X0.
Royalty Pharma says it is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the industry. It holds royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Johnson & Johnson's Tremfya, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, and royalties on 20 development-stage product candidates.
Trikafta: Vertex cystic fibrosis medicine on which Royalty Pharma holds a royalty Stage: commercial.
Trelegy: GSK product on which Royalty Pharma holds a royalty Stage: commercial.
$2.38 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Royalty Pharma plc reported net income of $770.9 million for the fiscal year ended Dec 31, 2025, and generated $2.49 billion of cash from operations, per its annual report to the SEC.
$452.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,2.03,5.02,5.03,9.01). Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Announced a share repurchase program. SEC Form 8-K (Items 7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio